• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Bienaime Jean Jacques bought $60,684 worth of shares (7,800 units at $7.78), increasing direct ownership by 33% to 31,415 units (SEC Form 4)

    3/26/25 4:05:21 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BIENAIME JEAN JACQUES

    (Last) (First) (Middle)
    C/O IMMUNOME, INC.
    18702 N. CREEK PARKWAY, SUITE 100

    (Street)
    BOTHELL WA 98011

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Immunome Inc. [ IMNM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/25/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/25/2025 P 7,800 A $7.78(1) 31,415 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The weighted average purchase price for the transaction report was $7.78, and the range of prices were between $7.37 and $8.51, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
    /s/ Sandra Stoneman, Attorney-in-Fact 03/26/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMNM

    DatePrice TargetRatingAnalyst
    4/2/2025$23.00Buy
    Lake Street
    11/8/2024$30.00Overweight
    Stephens
    5/31/2024$27.00Overweight
    Piper Sandler
    4/30/2024$24.00Overweight
    JP Morgan
    4/15/2024$35.00Buy
    Guggenheim
    1/29/2024$30.00Outperform
    Leerink Partners
    12/19/2023$12.00Outperform
    Wedbush
    10/29/2021$35.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $IMNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

      Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant

      2/11/25 8:30:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Appoints Roee Shahar as Executive Vice President, Commercial

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.

      10/8/24 8:05:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

      Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an

      7/9/24 7:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Immunome with a new price target

      Lake Street initiated coverage of Immunome with a rating of Buy and set a new price target of $23.00

      4/2/25 8:05:05 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Immunome with a new price target

      Stephens initiated coverage of Immunome with a rating of Overweight and set a new price target of $30.00

      11/8/24 8:17:18 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Immunome with a new price target

      Piper Sandler initiated coverage of Immunome with a rating of Overweight and set a new price target of $27.00

      5/31/24 7:43:20 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 164,500 shares of common stock to nine new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $8.8

      5/2/25 4:01:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first

      4/4/25 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 228,000 shares of common stock to five new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $6

      4/3/25 4:05:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Immunome Inc.

      DEFA14A - Immunome Inc. (0001472012) (Filer)

      4/24/25 4:07:28 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Immunome Inc.

      DEF 14A - Immunome Inc. (0001472012) (Filer)

      4/24/25 4:05:30 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Immunome Inc.

      S-8 - Immunome Inc. (0001472012) (Filer)

      3/19/25 5:10:27 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Higgins Jack exercised 5,200 shares at a strike of $1.35, increasing direct ownership by 38% to 18,729 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/28/25 5:54:02 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bienaime Jean Jacques bought $60,684 worth of shares (7,800 units at $7.78), increasing direct ownership by 33% to 31,415 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:05:21 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Siegall Clay B bought $999,459 worth of shares (137,100 units at $7.29), increasing direct ownership by 20% to 806,736 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:03:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Financials

    Live finance-specific insights

    See more
    • Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

      Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th

      3/28/24 4:02:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Third Quarter 2023 Financial Results

      - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

      11/9/23 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

      Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p

      3/16/23 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunome Inc.

      SC 13G/A - Immunome Inc. (0001472012) (Subject)

      11/14/24 9:00:58 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immunome Inc.

      SC 13G - Immunome Inc. (0001472012) (Subject)

      11/14/24 1:28:33 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immunome Inc.

      SC 13G - Immunome Inc. (0001472012) (Subject)

      11/14/24 10:33:51 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bienaime Jean Jacques bought $60,684 worth of shares (7,800 units at $7.78), increasing direct ownership by 33% to 31,415 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:05:21 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Siegall Clay B bought $999,459 worth of shares (137,100 units at $7.29), increasing direct ownership by 20% to 806,736 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:03:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bienaime Jean Jacques bought $57,470 worth of shares (7,000 units at $8.21), increasing direct ownership by 42% to 23,615 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/25/25 5:18:02 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care